Westlake Village BioPartners®

We are excited to announce the appointment of Tim Lugo as our new Chief Financial Officer and the addition of Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to our board of directors. Tim brings over two decades of experience in biotechnology finance and equity research, while Dr. Seidenberg and Dr. Tananbaum are seasoned venture capitalists. Their expertise will be instrumental as we scale and accelerate the development of our non-opioid pain medicines. Welcome to the Latigo Biotherapeutics, Inc. team! Click the link below to read the full press release. 👇 https://lnkd.in/gHJFupPx #NonOpioidPainRelief #Leadership #BioPharma

We are excited to announce our $325 million #SeriesC financing.  This new investment will enable ArsenalBio's ongoing development efforts and scale our manufacturing capabilities to develop T-cell medicines.  We thank the new investors along with our existing investors for their support in helping us to achieve our goal to defeat cancer. #celltherapy #patientsfirst https://lnkd.in/dimnsnfm

Today, we announced new Phase 1 data about the safety and tolerability of our therapeutic approach that may provide pain patients with an alternative to opioids. LTG-001 is an oral, selective Nav1.8 inhibitor in development to treat acute and chronic pain at its source. Opioid addiction is a national public health concern – 3.75 million Americans go on to long-term chronic opioid use after low-risk surgery as up to 19% of patients exposed to opioids develop dependency. We are also thrilled to welcome world-renowned analgesic scientist Neil Singla, MD as our chief medical officer. Learn more about these results and our commitment to provide effective, rapid-acting pain relief without the risk of addiction. https://lnkd.in/guXWFrrv #BioPharma #Biotechnology #Pharma #News #PainManagement #NonOpioid

Thanks to Nasdaq for their recognition of our recent launch! Westlake Village BioPartners®, 5AM Ventures, Foresite Capital, Corner Ventures #NASDAQ

Today, Boehringer Ingelheim and 3T Biosciences are pleased to announce a second partnership focused on discovering and developing next-generation #cancer #immunotherapies.    This new collaboration It brings together 3T’s best-in-class 3T-TRACE discovery platform with Boehringer Ingelheim’s commitment to develop first-in-class immuno-oncology treatments that boost the immune system’s ability to recognize, attack and kill tumors.   Read more about this collaboration in our press release: https://lnkd.in/griNxiqm

We are excited to share the appointment of Patricia Turney as Chief Technical Operations Officer. Patricia will join our Senior Leadership Team to oversee technical operations, CMC regulatory, corporate quality and facilities. With her impressive background and eager mindset, we're thrilled to welcome Patricia to our team during this important time for ACELYRIN. Welcome, Patricia! Read the full release here. https://lnkd.in/ecRzgUwu